Cargando…

The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells

The use of polyADPribose polymerase inhibitors in cancer treatment provides a unique opportunity to target DNA repair processes in cancer cells while leaving normal tissue intact. The PARP-1 enzyme repairs DNA single strand breaks (SSB). Therefore PARP-1 inhibition in BRCA1 negative cancers results...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourton, Emma C., Ahorner, Pia-Amata, Plowman, Piers N., Zahir, Sheba Adam, Al-Ali, Hussein, Parris, Christopher N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706007/
https://www.ncbi.nlm.nih.gov/pubmed/29187880
http://dx.doi.org/10.7150/jca.21338
_version_ 1783282140145778688
author Bourton, Emma C.
Ahorner, Pia-Amata
Plowman, Piers N.
Zahir, Sheba Adam
Al-Ali, Hussein
Parris, Christopher N.
author_facet Bourton, Emma C.
Ahorner, Pia-Amata
Plowman, Piers N.
Zahir, Sheba Adam
Al-Ali, Hussein
Parris, Christopher N.
author_sort Bourton, Emma C.
collection PubMed
description The use of polyADPribose polymerase inhibitors in cancer treatment provides a unique opportunity to target DNA repair processes in cancer cells while leaving normal tissue intact. The PARP-1 enzyme repairs DNA single strand breaks (SSB). Therefore PARP-1 inhibition in BRCA1 negative cancers results in the formation of cytotoxic DNA double strand breaks (DSB) causing synthetic lethality. The use of PARP1 inhibitors is gaining momentum in the treatment of a variety of tumours with BRCA1 involvement including breast, ovarian, pancreatic and prostate cancer. Our previous work showed that the PARP-1 inhibitor Olaparib causes both hypersensitivity of BRCA1(+/-) cells following exposure to gamma radiation due to the persistence of DNA strand breaks in cells, measured by the DNA damage biomarker γ-H2AX. Therefore dual treatment of cancers with radiotherapy and PARP1 inhibition may lead to cases of increased normal tissue toxicity in cancer patients. In this study we exposed two normal lymphoblastoid cell lines and three heterozygous BRCA1 lymphoblastoid cell lines to the PARP-1 inhibitor Olaparib and gamma radiation and after measured BRCA1 protein expression and apoptosis levels following treatment. BRCA1 protein foci analysis was performed on cells exposed to 2 Gy radiation in the presence or absence of 5 μM Olaparib. Using immunofluorescence and imaging flow cytometry, foci were measured in untreated cells and at 0.5, 3, 5 and 24 hours post-irradiation. Exposing normal and BRCA1(+/-) cells to Olaparib followed by gamma radiation results in a dramatic change in BRCA1 protein foci expression, with a significant reduction in BRCA1 protein expression observed in the heterozygote cells, together with an increase in apoptosis levels in these cells. In conclusion, combining PARP1 inhibitors with radiotherapy in treating of BRCA1-related cancers has clinical relevance, however this study and our previous publications serve to highlight the potential problems of increased side effects in these scenarios.
format Online
Article
Text
id pubmed-5706007
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-57060072017-11-29 The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells Bourton, Emma C. Ahorner, Pia-Amata Plowman, Piers N. Zahir, Sheba Adam Al-Ali, Hussein Parris, Christopher N. J Cancer Research Paper The use of polyADPribose polymerase inhibitors in cancer treatment provides a unique opportunity to target DNA repair processes in cancer cells while leaving normal tissue intact. The PARP-1 enzyme repairs DNA single strand breaks (SSB). Therefore PARP-1 inhibition in BRCA1 negative cancers results in the formation of cytotoxic DNA double strand breaks (DSB) causing synthetic lethality. The use of PARP1 inhibitors is gaining momentum in the treatment of a variety of tumours with BRCA1 involvement including breast, ovarian, pancreatic and prostate cancer. Our previous work showed that the PARP-1 inhibitor Olaparib causes both hypersensitivity of BRCA1(+/-) cells following exposure to gamma radiation due to the persistence of DNA strand breaks in cells, measured by the DNA damage biomarker γ-H2AX. Therefore dual treatment of cancers with radiotherapy and PARP1 inhibition may lead to cases of increased normal tissue toxicity in cancer patients. In this study we exposed two normal lymphoblastoid cell lines and three heterozygous BRCA1 lymphoblastoid cell lines to the PARP-1 inhibitor Olaparib and gamma radiation and after measured BRCA1 protein expression and apoptosis levels following treatment. BRCA1 protein foci analysis was performed on cells exposed to 2 Gy radiation in the presence or absence of 5 μM Olaparib. Using immunofluorescence and imaging flow cytometry, foci were measured in untreated cells and at 0.5, 3, 5 and 24 hours post-irradiation. Exposing normal and BRCA1(+/-) cells to Olaparib followed by gamma radiation results in a dramatic change in BRCA1 protein foci expression, with a significant reduction in BRCA1 protein expression observed in the heterozygote cells, together with an increase in apoptosis levels in these cells. In conclusion, combining PARP1 inhibitors with radiotherapy in treating of BRCA1-related cancers has clinical relevance, however this study and our previous publications serve to highlight the potential problems of increased side effects in these scenarios. Ivyspring International Publisher 2017-10-23 /pmc/articles/PMC5706007/ /pubmed/29187880 http://dx.doi.org/10.7150/jca.21338 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Bourton, Emma C.
Ahorner, Pia-Amata
Plowman, Piers N.
Zahir, Sheba Adam
Al-Ali, Hussein
Parris, Christopher N.
The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells
title The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells
title_full The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells
title_fullStr The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells
title_full_unstemmed The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells
title_short The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells
title_sort parp-1 inhibitor olaparib suppresses brca1 protein levels, increases apoptosis and causes radiation hypersensitivity in brca1(+/-) lymphoblastoid cells
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706007/
https://www.ncbi.nlm.nih.gov/pubmed/29187880
http://dx.doi.org/10.7150/jca.21338
work_keys_str_mv AT bourtonemmac theparp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells
AT ahornerpiaamata theparp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells
AT plowmanpiersn theparp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells
AT zahirshebaadam theparp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells
AT alalihussein theparp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells
AT parrischristophern theparp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells
AT bourtonemmac parp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells
AT ahornerpiaamata parp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells
AT plowmanpiersn parp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells
AT zahirshebaadam parp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells
AT alalihussein parp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells
AT parrischristophern parp1inhibitorolaparibsuppressesbrca1proteinlevelsincreasesapoptosisandcausesradiationhypersensitivityinbrca1lymphoblastoidcells